

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/758,679	01/15/2004	Jeremy E. Dahl	005950-845	4958
	7590 01/25/200 INGERSOLL & ROO	EXAMINER		
POST OFFICE	BOX 1404	VENCI, DAVID J		
ALEXANDRIA, VA 22313-1404			ART UNIT	PAPER NUMBER
			1641	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		01/25/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)		
Office Action Summary		10/758,679	DAHL ET AL.		
		Examiner	Art Unit		
	The MAILING DATE of this communication app	David J. Venci	1641		
Period fo	or Reply		orrespondence address		
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLICATION OF THE MAILING DISTRICT OF THE MAILING THE MAILIN	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
	Responsive to communication(s) filed on <i>Nove</i> This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final.			
Dispositi	ion of Claims				
5) □ 6) ⊠ 7) □ 8) ⊠ <b>Applicati</b> 9) ⊠ 10) ⊠	Claim(s) 1-40 is/are pending in the application 4a) Of the above claim(s) 1-28 is/are withdrawn Claim(s) is/are allowed.  Claim(s) 29-40 is/are rejected.  Claim(s) is/are objected to.  Claim(s) 1-40 are subject to restriction and/or of the specification is objected to by the Examine The drawing(s) filed on January 4, 2005 is/are:  Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The path or declaration is objected to by the Examine The path of the	n from consideration. election requirement. er. a) □ accepted or b) ☒ objected drawing(s) be held in abeyance. See ion is required if the drawing(s) is objected	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
2) 🔲 Notic 3) 🔯 Inforr	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date 07/12/04; 01/04/05; 08/29/05.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te		

Art Unit: 1641

**DETAILED ACTION** 

Election/Restrictions

Examiner acknowledges Applicants' election, with traverse, of Invention II, claims 29-40, in the reply filed

November 9, 2006. Applicants argue that "the inventions of Group I and II are so closely related that a

proper search of any of the claims would, by necessity, require a proper search of the others" (see

Applicants' reply, p. 2, first paragraph, first sentence).

Applicants' argument is not persuasive because a proper search of Invention II did not, in actuality,

require a proper search of Invention I (see the instant Office Action and PTO-892-Notice of References

Cited). The requirement is still deemed proper and is therefore made FINAL.

Claims 1-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a

nonelected Invention, there being no allowable generic or linking claim.

Currently, claims 29-40 are under examination.

Page 2

Art Unit: 1641

Information Disclosure Statement

The information disclosure statements filed July 12, 2004, and January 4, 2005, fail to comply with the

provisions of 37 CFR § 1.98(b)(5). According to Section 1.98(b)(5), each publication listed in an

information disclosure statement must be identified by publisher, authors, title, relevant pages, date, place

of publication, (e.g., publisher, authors, title, relevant pages, date, place of publication). Examiner has not

considered most of the 200+ publications in either of the disclosures.<sup>1</sup>

Specification

The disclosure is objected to because of the following informalities:

On p. 31, line 28, the phrase "This patent" lacks antecedent basis.

Literature citations appear missing from the paragraph beginning on p. 37, line 24.

Appropriate correction is required.

Applicant is advised that the date of any re-submission of any item of information contained in this information disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all certification requirements for statements under 37 CFR 1.97(e). See MPEP § 609.05(a).

Art Unit: 1641

## Drawings

Page 4

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.


The drawings are objected to under 37 CFR 1.83(a):

- 1. Fig. 1 fails to show "step 106" as described in the specification at p. 10, line 14.
- 2. Fig. 11A fails to show "self-assembled or crystallized material 1100" as described in the specification at p. 29, line 23.
- 3. Fig. 11B fails to show "molecular crystal 1101" as described in the specification at p. 30, line 12.

Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d).

In addition, the drawings are objected to as failing to comply with 37 CFR 1.84(p)(4) because reference character "1001" is used to designate both "diamondoid-containing material" and "molecular crystal".

Fig. 1 is further objected to because of the following undefined symbol:



Art Unit: 1641

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 29-40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to

particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claims 29, 37 and 28:

The term "heterodiamondoid" is indefinite. The identity of one or more member structures

belonging to the class "heterodiamondoid" is not clear. According to Specification page 3, lines

26-27: "[a] heteroatom is essentially an impurity atom that has been 'folded into' the diamond

lattice". Whether/how a "heterodiamondoid" possess a "diamond lattice" is not clear. How an

atom is "folded into" a diamond lattice is not clear. The identity of one ore more objects and/or

steps required for making or providing a diamond lattice having an atom "folded into" the diamond

lattice is not clear.

In claims 30-34, the phrase "the luminescent event" lacks antecedent basis.

In claim 35:

The essential structural cooperative relationship between "diamondoid lattice" and "diamondoid

lattice site" is not clear and appears omitted from the claim.

The essential structural cooperative relationship between "diamondoid lattice site" and "vacancy

or pore" is not clear and appears omitted from the claim.

Art Unit: 1641

The term "substitutionally" is indefinite. The identity of one or more reference points required for

Page 6

ascertaining "substitutionally" is not clear.

In claim 36:

The phrases "the diamondoid-containing material", "the bandgap" and "the bandgap of the

diamondoid-containing material" lack antecedent bases.

The infinitive "to create" is indefinite. Whether the act or process of "creating" is completed or

performed, or merely intended, is not clear. Whether the object(s) and/or steps required for

performing "positioning" are coextensive with the object(s) and/or steps required for performing

"creating" is not clear.

In claim 37:

The term "after" is indefinite. The identity of one or more temporal instances of "after" is not clear.

In claim 38:

How the step of claim 38 is incorporated into the method of claim 29 is not clear. Whether the

step of "reacting" in claim 38 references the step of "binding" in claim 29 is not clear. Whether the

object(s) and/or steps required for performing "reacting" are coextensive with the object(s) and/or

steps required for performing "binding" is not clear.

Art Unit: 1641

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 29-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Bronstein & Voyta (US 5,032,381).

Bronstein & Voyta describe a method of detecting a target analyte comprising the steps:

- (a) providing a heterodiamondoid-containing probe (see col. 9, Formula II);
- (b)(c) binding the heterodiamondoid-containing probe to the target analyte and exciting the biological label with energy (see col. 10, lines 29-32, "adding the chemiluminescent compound to the extracellular fluid so that it penetrates the cell and reaches the enzyme of interest that decomposes and activates said chemiluminescent compound");
- (d) detecting light emitted from the excited biological label (see Title, "chemiluminescence").

Art Unit: 1641

Claims 29-36 are rejected under 35 U.S.C. 102(e) as being anticipated by Bronstein (US 6,514,717).

Bronstein describes a method of detecting a target analyte comprising the steps:

(a) providing a heterodiamondoid-containing probe (see col. 1, lines 35-40, "a dioxetane having the formula..."; see also, col. 2, lines 19-20, "group T of the dioxetane is a polycycloalkyl group, preferably adamantyl"; see also, Table 1);

(b)(c) binding the heterodiamondoid-containing probe to the target analyte and exciting the biological label with energy (see col. 11, lines 37-43, "a dioxetane[...] is added", "The enzyme cleaves group Z", "chromophore Y[...] is thus excited") (paraphrasing mine);

(d) detecting light emitted from the excited biological label (see Abstract, "chemiluminescence").

Page 8

Art Unit: 1641

Page 9

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 29-38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Huang et al. (US 7,070,921) in view of Bronstein (US 6,514,717).

Huang et al. describe a method of detecting a target analyte comprising the steps:

- (a) providing a probe (see e.g., Fig. 6, "A\*");
- (b)(c) binding the probe to the target analyte and exciting the biological label with energy (see e.g., Fig. 6, "A ↔ A\*"; see also, col. 14, lines 37-40, "the detectable response may be generated directly using a luminophore associated with[...] A\*") (paraphrasing mine);
- (d) detecting light emitted from the excited biological label (see Abstract, "chemiluminescence").

Huang et al. do not describe a "heterodiamondoid-containing" probe.

However, Bronstein describe a heterodiamondoid-containing probe (see col. 1, lines 35-40, "a dioxetane having the formula..."; col. 2, lines 19-20, "group T of the dioxetane is a polycycloalkyl group, preferably adamantyl") for use in enzyme-amplified assays (see e.g., col. 2, line 48, "amplification effect").

Art Unit: 1641

Page 10

It would have been obvious for a person of ordinary skill to perform the analyte detection method of Huang *et al.* with "heterodiamondoid-containing" probes because Bronstein discovered that "an external excitation energy source, e.g., light, is not necessary" with heterodiamondoid-containing probes. Furthermore, Bronstein discovered that heterodiamondoid-containing probes resulted in enzymeamplified assays having optimal decomposition and luminescence kinetics (see col. 3, lines 3-12).

Art Unit: 1641

Page 11

Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Venci whose telephone number is 571-272-2879. The examiner can normally be reached on 08:00 - 16:30 (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

David J Venci Examiner Art Unit 1641

djv

LONG V. LE 01/25

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600